DarioHealth Corp. (DRIO): Price and Financial Metrics

DarioHealth Corp. (DRIO): $4.01

0.06 (+1.52%)

POWR Rating

Component Grades














  • Growth is the dimension where DRIO ranks best; there it ranks ahead of 76.43% of US stocks.
  • DRIO's strongest trending metric is Stability; it's been moving up over the last 177 days.
  • DRIO's current lowest rank is in the Momentum metric (where it is better than 1.17% of US stocks).

DRIO Stock Summary

  • DRIO's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 19.05% of US stocks.
  • With a year-over-year growth in debt of 9,672.82%, DARIOHEALTH CORP's debt growth rate surpasses 99.58% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for DRIO comes in at -58.82% -- higher than that of only 9.66% of stocks in our set.
  • Stocks that are quantitatively similar to DRIO, based on their financial statements, market capitalization, and price volatility, are IGC, RSKD, PAVM, STXS, and AFRM.
  • Visit DRIO's SEC page to see the company's official filings. To visit the company's web site, go to mydario.com.

DRIO Valuation Summary

  • In comparison to the median Healthcare stock, DRIO's price/sales ratio is 19.15% lower, now standing at 3.8.
  • DRIO's price/sales ratio has moved NA NA over the prior 120 months.

Below are key valuation metrics over time for DRIO.

Stock Date P/S P/B P/E EV/EBIT
DRIO 2023-03-24 3.8 1.3 -1.6 -1.4
DRIO 2023-03-23 3.8 1.3 -1.7 -1.4
DRIO 2023-03-22 4.0 1.4 -1.8 -1.5
DRIO 2023-03-21 4.0 1.4 -1.7 -1.4
DRIO 2023-03-20 3.7 1.3 -1.6 -1.3
DRIO 2023-03-17 3.8 1.3 -1.6 -1.3

DRIO Growth Metrics

    Its 2 year net income to common stockholders growth rate is now at -198.41%.
  • The 5 year net cashflow from operations growth rate now stands at -74.04%.
  • The 5 year cash and equivalents growth rate now stands at 461.8%.
DRIO's revenue has moved up $19,316,000 over the prior 33 months.

The table below shows DRIO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 26.875 -55.04 -73.025
2022-06-30 25.899 -56.78 -79.831
2022-03-31 24.977 -57.971 -79.623
2021-12-31 20.513 -50.409 -78.766
2021-09-30 16.565 -42.033 -66.359
2021-06-30 12.978 -33.39 -50.907

DRIO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DRIO has a Quality Grade of F, ranking ahead of 2.68% of graded US stocks.
  • DRIO's asset turnover comes in at 0.156 -- ranking 147th of 186 Medical Equipment stocks.
  • SPNE, ATRI, and ICAD are the stocks whose asset turnover ratios are most correlated with DRIO.

The table below shows DRIO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.156 0.284 28.266
2021-03-31 0.174 0.296 38.633
2020-12-31 0.266 0.332 847.338
2020-09-30 0.283 0.384 132.027
2020-06-30 0.404 0.439 -93.685
2020-03-31 0.426 0.403 -274.333

DRIO Price Target

For more insight on analysts targets of DRIO, see our DRIO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $27.53 Average Broker Recommendation 1.5 (Moderate Buy)

DRIO Stock Price Chart Interactive Chart >

Price chart for DRIO

DRIO Price/Volume Stats

Current price $4.01 52-week high $7.69
Prev. close $3.95 52-week low $3.53
Day low $3.96 Volume 42,594
Day high $4.08 Avg. volume 158,618
50-day MA $4.87 Dividend yield N/A
200-day MA $4.97 Market Cap 103.75M

DarioHealth Corp. (DRIO) Company Bio

DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada. The company's flagship product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with Dario Blood Glucose Monitoring System, a pocket-sized, blood glucose monitoring device. It offers DarioEngage software platform, where the company digitally engages with Dario users and assists them in monitoring their chronic illnesses, as well as provides them with coaching, support, digital communications; and real time alerts, trends, and pattern analysis. DarioHealth Corp. markets its products directly to consumer cash sales, as well as retail pharmacy, hospitals, and distributors; and through online. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is headquartered in Caesarea, Israel.

DRIO Latest News Stream

Event/Time News Detail
Loading, please wait...

DRIO Latest Social Stream

Loading social stream, please wait...

View Full DRIO Social Stream

Latest DRIO News From Around the Web

Below are the latest news stories about DARIOHEALTH CORP that investors may wish to consider to help them evaluate DRIO as an investment opportunity.

Dario Selected as Digital Therapeutics Partner by a Top-Ten Digitally Enabled Pharmacy Benefits Manager

DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, announced a new contract with a leading nationwide Pharmacy Benefits Manager (the "PBM") operating in 50 states to provide Dario's digital therapeutics, starting with the diabetes solution, to employer clients beginning in the second quarter of 2023.

Yahoo | March 27, 2023

Dario Announces Strategic Partnership with Amwell to Expand Access to its Cardiometabolic Digital Therapeutic Solution

DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, announced today a strategic partnership with Amwell® (NYSE: AMWL), a leader in digital healthcare enablement, to deliver its cardiometabolic solution to Amwell customers. Dario's solution will be available through Amwell beginning in the second half of 2023.

Yahoo | March 22, 2023

Dario Publishes New Research Demonstrating Digital Personalization of Pain Management with Adapted Machine Learning

DarioHealth Corp. (Nasdaq: DRIO)(the "Company" or "Dario"), a leader in the global digital therapeutics (DTx) market, announced today new research published in Pain Reports investigating personalized efficacy of digital therapeutics for pain management, linking the reduction of back pain for users in a digital posture training program with the personalization of user journeys adapting machine learning models.

Yahoo | March 14, 2023

The DarioHealth Corp. (NASDAQ:DRIO) Annual Results Are Out And Analysts Have Published New Forecasts

There's been a notable change in appetite for DarioHealth Corp. ( NASDAQ:DRIO ) shares in the week since its yearly...

Yahoo | March 12, 2023

DarioHealth Reports Fourth Quarter and Record Revenue in Full-Year 2022 Financial and Operating Results

DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital therapeutics (DTx) market, today reported financial results for the fourth quarter and full year 2022 and provided a corporate and commercial update.

Yahoo | March 9, 2023

Read More 'DRIO' Stories Here

DRIO Price Returns

1-mo -12.83%
3-mo -6.31%
6-mo -13.39%
1-year -32.49%
3-year -38.78%
5-year -86.98%
YTD -6.31%
2022 -67.00%
2021 -9.24%
2020 117.84%
2019 -57.95%
2018 -51.25%

Continue Researching DRIO

Want to see what other sources are saying about DarioHealth Corp's financials and stock price? Try the links below:

DarioHealth Corp (DRIO) Stock Price | Nasdaq
DarioHealth Corp (DRIO) Stock Quote, History and News - Yahoo Finance
DarioHealth Corp (DRIO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8355 seconds.